SCHEMBL6724052

SCHEMBL6724052

Cn1c2ccccc2c2cc(-c3ccccc3-c3ccccc3)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 1/20 0.55
HSD17B10 Q99714 6/20 0.54
KDM4E B2RXH2 3/20 0.53
HPGD P15428 4/20 0.51
ALDH1A1 P00352 4/20 0.51
KMT2A Q03164 3/20 0.51
MAPT P10636 2/20 0.51
MEN1 O00255 1/20 0.51
HTT P42858 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
PABPC1 P11940 1/20 0.43
KIF11 P52732 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6724055 0.95 HSD17B10 (0.50) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL17809442 0.93 GPR3 (0.59) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL22705859 0.89 HSD17B10 (0.44) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL19986208 0.87 GPR3 (0.61) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL883712 0.87 GPR3 (0.61) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL19986207 0.87 GPR3 (0.61) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL6724269 0.87 GPR3 (0.61) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL22707070 0.87 HSD17B10 (0.46) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL22706290 0.85 HSD17B10 (0.44) GPR3HSD17B10KDM4EHPGDALDH1A1
SCHEMBL22706906 0.85 HSD17B10 (0.44) GPR3HSD17B10KDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178216-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-15 US disclosed
US-8178216-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-05-15 US disclosed
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-03-19 US disclosed
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090072718-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device including quinoxaline derivative CRY1, GRK1, CRY2 GPR3 1225/4885HSD17B10 2259/4885KDM4E 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.